Is  M cl‐1 L  the new anti‐apoptotic effector of  B ‐ RAFV  600E  in melanoma? | Zendy

Bergamaschi Daniele | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Is M cl‐1 L the new anti‐apoptotic effector of B ‐ RAFV 600E in melanoma?

Author(s) -

Bergamaschi Daniele

Publication year - 2014

Publication title -

experimental dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.108

H-Index - 96

eISSN - 1600-0625

pISSN - 0906-6705

DOI - 10.1111/exd.12312

Subject(s) - melanoma , apoptosis , in vivo , effector , cancer research , chemistry , microbiology and biotechnology , biology , genetics

A recent report has unveiled a novel mechanism by which oncogenic BRAF signalling might trigger apoptotic resistance in melanoma by selectively affecting the expression of B cl‐2 family member M cl‐1 L ( Exp Dermatol 2013: 22 : 767). Correlation of M cl‐1 splice variants and B ‐ RAF mutational status was determined in a panel of melanoma cell lines. In vivo validation of this mechanism, which is supported by recent literature, might provide novel therapeutic approaches such as the use of targeted M cl‐1 inhibitors to improve outcome in melanoma.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research